Shayaq Ul Abeer Rasool
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shayaq Ul Abeer Rasool has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Shajrul Amin
Department of Biochemistry, University of Kashmir, Hazratbal, India
12 shared publications Mudasar Nabi
Department of Biochemistry, Government Medical College, Srinagar, India
11 shared publicationsSairish Ashraf
Department of Biochemistry, University of Kashmir, Srinagar, India
9 shared publications- Arshad Ahmad Pandith
Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, India
6 shared publications Adil Lateef
Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar-190011, J&K-India
4 shared publicationsSyed Mudasir Andrabi
Division of Biotechnology, Faculty of Veterinary Sciences and Animal Husbandry, Shuhama, Sher-e-Kashmir University of Agricultural Sciences and Technology, Kashmir, India
4 shared publications
Latest Publications
- Open Access
- 5 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
IL-11–IL6ST–STAT3 signaling defines a convergent inflammatory axis in esophageal cancer subtypes
Esophageal cancer (EC) is an aggressive malignancy characterized by poor survival outcomes and strong links to chronic inflammatory signaling. Interleukin-11 (IL-11) has emerged as a cytokine of interest in tumorigenesis and therapy resistance. This study investigated the expression, prognostic implications and functional relevance of IL-11 signaling in EC. IL-11 pathway components were analyzed in 50 surgically resected EC and adjacent normal tissues using RT-qPCR and immunohistochemistry (IHC). Histological subtype-stratified analyses were performed for esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). Functional assays in KYSE-410 cells evaluated the effect of IL-11 neutralization on viability, migration, and pathway activation. RNA-sequencing, reverse-phase protein array (RPPA), clinical, and survival data from the TCGA-ESCA cohort were analyzed to validate pathway activation and prognostic associations. Additionally, murine RNA-sequencing datasets following anti-IL-11 or anti-IL-11 receptor treatment were examined to assess downstream transcriptional effects. IL-11, COX-2, and STAT3 mRNA levels were significantly upregulated in tumors compared with matched normal epithelium (p < 0.05) accompanied by increased nuclear phosphorylation of STAT3 (Tyr705). TCGA analyses confirmed elevated expression of IL-11 pathway components in EC. Elevated IL11 expression showed a trend toward reduced overall survival and was significantly associated with poorer disease-free survival. While IL11, STAT3, and PTGS2 expression did not differ significantly between EAC and ESCC, receptor-level signaling components IL6ST (gp130) and JAK1 were significantly higher in EAC, with RPPA data demonstrating increased pSTAT3 (Tyr705) and e-cadherin levels in this subtype. Downstream transcriptional analyses revealed subtype-specific STAT3 programs, with proliferation and invasion genes enriched in ESCC and survival-associated mediators elevated in EAC. Neutralization of IL11 significantly reduced cell viability (IC50 = 1 µg/mL), impaired migration, and suppressed pSTAT3 activation. These findings identify the IL-11/IL6ST/JAK1/STAT3/COX-2 axis as a central inflammatory signaling pathway in esophageal cancer. Although ligand expression is comparable across subtypes, receptor-level signaling in EAC suggests pathway sensitization rather than ligand abundance as a key determinant of signaling intensity. Functional inhibition of IL-11 attenuates tumor-promoting phenotypes, supporting IL-11 signaling as a biologically relevant and potentially pan-histologic therapeutic target in esophageal cancer.
- 5 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessIL-11–IL6ST–STAT3 signaling defines a convergent inflammatory axis in esophageal cancer subtypes
Esophageal cancer (EC) is an aggressive malignancy characterized by poor survival outcomes and strong links to chronic inflammatory signaling. Interleukin-11 (IL-11) has emerged as a cytokine of interest in tumorigenesis and therapy resistance. This study investigated the expression, prognostic implications and functional relevance of IL-11 signaling in EC. IL-11 pathway components were analyzed in 50 surgically resected EC and adjacent normal tissues using RT-qPCR and immunohistochemistry (IHC). Histological subtype-stratified analyses were performed for esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). Functional assays in KYSE-410 cells evaluated the effect of IL-11 neutralization on viability, migration, and pathway activation. RNA-sequencing, reverse-phase protein array (RPPA), clinical, and survival data from the TCGA-ESCA cohort were analyzed to validate pathway activation and prognostic associations. Additionally, murine RNA-sequencing datasets following anti-IL-11 or anti-IL-11 receptor treatment were examined to assess downstream transcriptional effects. IL-11, COX-2, and STAT3 mRNA levels were significantly upregulated in tumors compared with matched normal epithelium (p < 0.05) accompanied by increased nuclear phosphorylation of STAT3 (Tyr705). TCGA analyses confirmed elevated expression of IL-11 pathway components in EC. Elevated IL11 expression showed a trend toward reduced overall survival and was significantly associated with poorer disease-free survival. While IL11, STAT3, and PTGS2 expression did not differ significantly between EAC and ESCC, receptor-level signaling components IL6ST (gp130) and JAK1 were significantly higher in EAC, with RPPA data demonstrating increased pSTAT3 (Tyr705) and e-cadherin levels in this subtype. Downstream transcriptional analyses revealed subtype-specific STAT3 programs, with proliferation and invasion genes enriched in ESCC and survival-associated mediators elevated in EAC. Neutralization of IL11 significantly reduced cell viability (IC50 = 1 µg/mL), impaired migration, and suppressed pSTAT3 activation. These findings identify the IL-11/IL6ST/JAK1/STAT3/COX-2 axis as a central inflammatory signaling pathway in esophageal cancer. Although ligand expression is comparable across subtypes, receptor-level signaling in EAC suggests pathway sensitization rather than ligand abundance as a key determinant of signaling intensity. Functional inhibition of IL-11 attenuates tumor-promoting phenotypes, supporting IL-11 signaling as a biologically relevant and potentially pan-histologic therapeutic target in esophageal cancer.
- Open Access
- 4 December 2025
- Vol. 29 (1) , 219-226
Polymorphic Variants of FOXP3 Gene (rs 3761548) and (rs 3761549) are Significantly Associated with the Risk for Recurrent Pregnancy Losses. A Study in High Incidence Zone (Kashmir, North India).
Recurrent Pregnancy Loss (RPL) is a significant pregnancy complication with a multifactorial aetiology and is a vital reproductive health concern that globally affects 2-5% of women. Polymorphic gene variation causes alteration in FOXP3 gene that impairs the Treg cells which leads to complications in pregnancy outcome. Thus, we aimed to study an association between FOXP3 polymorphic variations (rs3761548 and rs3761549) and RPL. This case control study comprised of 120 RPL cases and 150 healthy multiparous women as control group with at least one full term pregnancy and no history of pregnancy loss matched to cases according to age and geographic origins. Genotyping for FOXP3 was analyzed by polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP). Significantly higher frequency of FOXP3 -3279 C/A (rs 3761548)heterozygous AC and homozygous AA was found in RPL cases than controls (63.3% vs. 46%, O.R = 2.53): p = 0.0006 and (11.7% vs. 8%; O.R 2.68): p = 0.03 respectively. Moreover, the dominant model (AC +AA) and allele A were seen implicated more in RPL cases vs. healthy control (75% vs. 54%; O.R = 2.5): p = 0.0005 and (43.3% vs. 31%; O.R = 1.7): p = 0.003. For FOXP3 -2383 C/T (rs 3761548), homozygous genotype TT was significantly higher in RPL cases than the control group against the wild type CC genotype with O. R= 3.49 (p = 0.04). Further, FOXP3 (rs 3761548) genotypes AC+AA were significantly associated between cases and control in terms of women without any known family history (p = 0.0009) and consanguinity (p = 0.0002), respectively. The study concludes that both the variants of FOXP3 gene, C/A (-3279) and C/T (-2383) are significantly associated with an increased risk for recurrent pregnancy losses.
- 4 December 2025
- Vol. 29 (1) , 219-226
Open AccessPolymorphic Variants of FOXP3 Gene (rs 3761548) and (rs 3761549) are Significantly Associated with the Risk for Recurrent Pregnancy Losses. A Study in High Incidence Zone (Kashmir, North India).
Recurrent Pregnancy Loss (RPL) is a significant pregnancy complication with a multifactorial aetiology and is a vital reproductive health concern that globally affects 2-5% of women. Polymorphic gene variation causes alteration in FOXP3 gene that impairs the Treg cells which leads to complications in pregnancy outcome. Thus, we aimed to study an association between FOXP3 polymorphic variations (rs3761548 and rs3761549) and RPL. This case control study comprised of 120 RPL cases and 150 healthy multiparous women as control group with at least one full term pregnancy and no history of pregnancy loss matched to cases according to age and geographic origins. Genotyping for FOXP3 was analyzed by polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP). Significantly higher frequency of FOXP3 -3279 C/A (rs 3761548)heterozygous AC and homozygous AA was found in RPL cases than controls (63.3% vs. 46%, O.R = 2.53): p = 0.0006 and (11.7% vs. 8%; O.R 2.68): p = 0.03 respectively. Moreover, the dominant model (AC +AA) and allele A were seen implicated more in RPL cases vs. healthy control (75% vs. 54%; O.R = 2.5): p = 0.0005 and (43.3% vs. 31%; O.R = 1.7): p = 0.003. For FOXP3 -2383 C/T (rs 3761548), homozygous genotype TT was significantly higher in RPL cases than the control group against the wild type CC genotype with O. R= 3.49 (p = 0.04). Further, FOXP3 (rs 3761548) genotypes AC+AA were significantly associated between cases and control in terms of women without any known family history (p = 0.0009) and consanguinity (p = 0.0002), respectively. The study concludes that both the variants of FOXP3 gene, C/A (-3279) and C/T (-2383) are significantly associated with an increased risk for recurrent pregnancy losses.
- Open Access
- 22 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Overexpression of androgen receptor signalling transactivator lncRNAs PRNCR1 and PCGEM1 are associated with the increased risk of PCOS
PCOS, a common disorder in reproductive aged women, characterized by hyperandrogenism. Hyperandrogenism can be attributed to the hyperactive androgen receptor (AR). Androgen receptor mediated signalling involves the association of multiple coregulators and any aberrant activity of these factors may disrupt the normal transcriptional activity of AR and hence may act as contributing factors in pathophysiology of hyperandrogenic disorders. LncRNAs PRNCR1 and PCGEM1 act as AR coactivators. The study was aimed at determining the association of these lncRNAs with PCOS. A total of 178 participants including 105 PCOS cases and 73 controls were recruited. The Anthropometric, Metabolic and hormonal characteristics of the participants were determined. Total RNA was isolated and reverse transcribed into cDNA. Quantitative real-time PCR was done to study the expression pattern of lncRNAs. The association between different parameters with the expression of PRNCR1 and PCGEM1 was determined by correlation analysis. The expression levels of PRNCR1 (PRNCR1, 5.28 (1.29–9.14) versus 1.07 (0.05–3.18); P < 0.001) (PCGEM1, 3.08 (0.29–8.79) versus 1.70 (0.116–3.73); P < 0.001) were significantly higher in Women with PCOS compared to controls. Furthermore, lncRNA PRNCR1 showed a positive correlation with testosterone (P < 0.001). ROC analysis showed a strong diagnostic performance of lncRNA PRNCR1 Optimal Cut off (Youden’s Index) = 3.23, AUC = 0.988 (95% CI = 0.976–0.99) and Sensitivity = 0.91, Specificity = 1.00 and for PCGEM1 Optimal Cut off (Youden’s Index) = 2.02, AUC = 0.86 (95% CI = 0.81–0.92) and Sensitivity = 0.82, Specificity: 0.90. Our results demonstrated that overexpression of AR coactivator lncRNAs PRNCR1 and PCGEM1 are associated with an increased risk of PCOS in Kashmiri women. These lncRNAs may act as important factors for the hyperactivation of AR and subsequent overexpression of AR regulated genes and thus may contribute towards the pathogenesis of PCOS and its clinical manifestations.
- 22 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Open AccessOverexpression of androgen receptor signalling transactivator lncRNAs PRNCR1 and PCGEM1 are associated with the increased risk of PCOS
PCOS, a common disorder in reproductive aged women, characterized by hyperandrogenism. Hyperandrogenism can be attributed to the hyperactive androgen receptor (AR). Androgen receptor mediated signalling involves the association of multiple coregulators and any aberrant activity of these factors may disrupt the normal transcriptional activity of AR and hence may act as contributing factors in pathophysiology of hyperandrogenic disorders. LncRNAs PRNCR1 and PCGEM1 act as AR coactivators. The study was aimed at determining the association of these lncRNAs with PCOS. A total of 178 participants including 105 PCOS cases and 73 controls were recruited. The Anthropometric, Metabolic and hormonal characteristics of the participants were determined. Total RNA was isolated and reverse transcribed into cDNA. Quantitative real-time PCR was done to study the expression pattern of lncRNAs. The association between different parameters with the expression of PRNCR1 and PCGEM1 was determined by correlation analysis. The expression levels of PRNCR1 (PRNCR1, 5.28 (1.29–9.14) versus 1.07 (0.05–3.18); P < 0.001) (PCGEM1, 3.08 (0.29–8.79) versus 1.70 (0.116–3.73); P < 0.001) were significantly higher in Women with PCOS compared to controls. Furthermore, lncRNA PRNCR1 showed a positive correlation with testosterone (P < 0.001). ROC analysis showed a strong diagnostic performance of lncRNA PRNCR1 Optimal Cut off (Youden’s Index) = 3.23, AUC = 0.988 (95% CI = 0.976–0.99) and Sensitivity = 0.91, Specificity = 1.00 and for PCGEM1 Optimal Cut off (Youden’s Index) = 2.02, AUC = 0.86 (95% CI = 0.81–0.92) and Sensitivity = 0.82, Specificity: 0.90. Our results demonstrated that overexpression of AR coactivator lncRNAs PRNCR1 and PCGEM1 are associated with an increased risk of PCOS in Kashmiri women. These lncRNAs may act as important factors for the hyperactivation of AR and subsequent overexpression of AR regulated genes and thus may contribute towards the pathogenesis of PCOS and its clinical manifestations.
- Open Access
- 28 June 2024
- Published by Spandidos Publications in World Academy of Sciences Journal
- Vol. 6 (5) , 1-8
Inflammatory mediator profile of hospitalised patients with COVID‑19 during the second wave of the pandemic: A comparative study
Cough, fever and tiredness are upper respiratory symptoms of coronavirus disease 2019 (COVID‑19). The emergence of the Delta variant, a significantly mutated and highly transmissible form of the severe acute respiratory syndrome coronavirus 2, initiated a fresh global wave of the COVID-19 pandemic. The timely and accurate clinical outcome prediction is vital for improving the management of patients with COVID‑19 and identifying those who may be severely ill. In this retrospective observational study, a comparison of signs and symptoms and laboratory values was conducted between survivors and non-survivors of the second wave of COVID-19. Severe acute respiratory syndrome coronavirus 2‑positive cases between June, 2021 and January, 2022 were confirmed using reverse transcriptase‑polymerase chain reaction. Medical records were reviewed and collected until patient discharge/mortality. The levels of inflammatory biomarkers, symptoms and comorbidities of the patients were assessed. Analyses were performed using SPSS version 20.0. Of the 200 patients with COVID‑19, 112 were male and 88 were female. Non-survivors outnumbered survivors, with the most common symptoms being sputum production, coughing, and hemoptysis (P≤0.01). Chronic kidney disease and chronic obstructive pulmonary disease were the most common co‑occurring conditions among the non‑survivors. On the day of admission, interleukin (IL)‑6 OR=1.003 (1.000‑1.007), C‑reactive protein OR=1.038 (1.016‑1.059) and lactate dehydrogenase OR=1.004 (1.001‑1.006) levels were measured; however, the most significant predictor of morality were the D‑dimer levels OR=1.016 (1.002‑1.059). Serum ferritin and D‑dimer levels were considerably higher in non‑survivors than in survivors, while IL‑6, C‑reactive protein and lactate dehydrogenase levels were significantly higher in survivors at the time of admission. On day 3 of admission, serum ferritin, D‑dimer, and IL‑6 levels were higher in non‑survivors than in the survivors of COVID‑19. The following factors continued to be significant predictors of mortality among COVID‑19 patients with binary logistic regression: Age, sputum, haemoptysis, cough and chronic obstructive pulmonary disease. Logistic regression analysis revealed that chronic kidney disease was not statistically significant. Understanding the variations in inflammatory profiles is crucial for devising personalized treatment strategies and improving clinical outcomes in the ongoing battle against COVID‑19.
- 28 June 2024
- Published by Spandidos Publications in World Academy of Sciences Journal
- Vol. 6 (5) , 1-8
Open AccessInflammatory mediator profile of hospitalised patients with COVID‑19 during the second wave of the pandemic: A comparative study
Cough, fever and tiredness are upper respiratory symptoms of coronavirus disease 2019 (COVID‑19). The emergence of the Delta variant, a significantly mutated and highly transmissible form of the severe acute respiratory syndrome coronavirus 2, initiated a fresh global wave of the COVID-19 pandemic. The timely and accurate clinical outcome prediction is vital for improving the management of patients with COVID‑19 and identifying those who may be severely ill. In this retrospective observational study, a comparison of signs and symptoms and laboratory values was conducted between survivors and non-survivors of the second wave of COVID-19. Severe acute respiratory syndrome coronavirus 2‑positive cases between June, 2021 and January, 2022 were confirmed using reverse transcriptase‑polymerase chain reaction. Medical records were reviewed and collected until patient discharge/mortality. The levels of inflammatory biomarkers, symptoms and comorbidities of the patients were assessed. Analyses were performed using SPSS version 20.0. Of the 200 patients with COVID‑19, 112 were male and 88 were female. Non-survivors outnumbered survivors, with the most common symptoms being sputum production, coughing, and hemoptysis (P≤0.01). Chronic kidney disease and chronic obstructive pulmonary disease were the most common co‑occurring conditions among the non‑survivors. On the day of admission, interleukin (IL)‑6 OR=1.003 (1.000‑1.007), C‑reactive protein OR=1.038 (1.016‑1.059) and lactate dehydrogenase OR=1.004 (1.001‑1.006) levels were measured; however, the most significant predictor of morality were the D‑dimer levels OR=1.016 (1.002‑1.059). Serum ferritin and D‑dimer levels were considerably higher in non‑survivors than in survivors, while IL‑6, C‑reactive protein and lactate dehydrogenase levels were significantly higher in survivors at the time of admission. On day 3 of admission, serum ferritin, D‑dimer, and IL‑6 levels were higher in non‑survivors than in the survivors of COVID‑19. The following factors continued to be significant predictors of mortality among COVID‑19 patients with binary logistic regression: Age, sputum, haemoptysis, cough and chronic obstructive pulmonary disease. Logistic regression analysis revealed that chronic kidney disease was not statistically significant. Understanding the variations in inflammatory profiles is crucial for devising personalized treatment strategies and improving clinical outcomes in the ongoing battle against COVID‑19.
- Open Access
- 12 June 2024
- Published by Xia & He Publishing in Gene Expression
- Vol. 000 (000) , 000
HLA-G Polymorphic Variation (G*0104N exon 3) Confers Potential Risk for Recurrent Pregnancy Losses: A Study in a High Incidence Zone (Kashmir, North India)
HLA-G gene harbors certain polymorphic variations that can potentially impact its biological activity, and therefore, may confer a risk for recurrent pregnancy loss (RPL). This study aimed to analyze whether HLA-G polymorphic variations (G*0103, G*0104, and G0105N) are related to the risk of RPL in women from Kashmir, North India.
- 12 June 2024
- Published by Xia & He Publishing in Gene Expression
- Vol. 000 (000) , 000
Open AccessHLA-G Polymorphic Variation (G*0104N exon 3) Confers Potential Risk for Recurrent Pregnancy Losses: A Study in a High Incidence Zone (Kashmir, North India)
HLA-G gene harbors certain polymorphic variations that can potentially impact its biological activity, and therefore, may confer a risk for recurrent pregnancy loss (RPL). This study aimed to analyze whether HLA-G polymorphic variations (G*0103, G*0104, and G0105N) are related to the risk of RPL in women from Kashmir, North India.
- Open Access
- 8 April 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-10
Significance and implications of FHIT gene expression and promoter hypermethylation in acute lymphoblastic leukemia (ALL)
Background: Fragile histidine triad (FHIT) has been documented to play a vital role in various cancers including acute lymphoblastic leukemia (ALL). Keeping in view the plausible role of FHIT gene, we aimed to examine DNA promoter hypermethylation and mRNA expression in ALL cases in Kashmir (North India). Methods: A total of 66 cases of ALL were analyzed for FHIT mRNA expression and promoter methylation by qRT-PCR and Methylation Specific-PCR (MS-PCR) respectively. Results: FHIT mRNA expression showed significantly decreased expression in ALL cases with mean fold change of 9.24 ± 5.44 as compared to healthy controls (p = 0.01). The pattern of FHIT deregulation in ALL cases differed significantly between decreased and increased expression (p < 0.0001). A threefold decreased expression was observed in 75% of ALL cases than healthy controls (− 3.58 ± 2.32). ALL patients with FHIT gene promoter hypermethylation presented significantly higher in 80% (53/66) of cases (p = 0.0005). The association of FHIT gene hypermethylation and its subsequent expression showed FHIT mRNA expression as significantly lower in ALL cases with hypermethylation (p = 0.0008). B-ALL cases exhibited a highly significant association between the methylation pattern and its mRNA expression (p = 0.000). In low range WBC group, a significant association was found between increased expression (26%) of the cases and methylated (4%)/unmethylated group 86% (p = 0.0006). Conclusion: The present study conclude that FHIT gene hypermethylation and its altered expression may be linked in the pathogenesis of ALL and provide an evidence for the role of FHIT in the development of ALL.
- 8 April 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-10
Open AccessSignificance and implications of FHIT gene expression and promoter hypermethylation in acute lymphoblastic leukemia (ALL)
Background: Fragile histidine triad (FHIT) has been documented to play a vital role in various cancers including acute lymphoblastic leukemia (ALL). Keeping in view the plausible role of FHIT gene, we aimed to examine DNA promoter hypermethylation and mRNA expression in ALL cases in Kashmir (North India). Methods: A total of 66 cases of ALL were analyzed for FHIT mRNA expression and promoter methylation by qRT-PCR and Methylation Specific-PCR (MS-PCR) respectively. Results: FHIT mRNA expression showed significantly decreased expression in ALL cases with mean fold change of 9.24 ± 5.44 as compared to healthy controls (p = 0.01). The pattern of FHIT deregulation in ALL cases differed significantly between decreased and increased expression (p < 0.0001). A threefold decreased expression was observed in 75% of ALL cases than healthy controls (− 3.58 ± 2.32). ALL patients with FHIT gene promoter hypermethylation presented significantly higher in 80% (53/66) of cases (p = 0.0005). The association of FHIT gene hypermethylation and its subsequent expression showed FHIT mRNA expression as significantly lower in ALL cases with hypermethylation (p = 0.0008). B-ALL cases exhibited a highly significant association between the methylation pattern and its mRNA expression (p = 0.000). In low range WBC group, a significant association was found between increased expression (26%) of the cases and methylated (4%)/unmethylated group 86% (p = 0.0006). Conclusion: The present study conclude that FHIT gene hypermethylation and its altered expression may be linked in the pathogenesis of ALL and provide an evidence for the role of FHIT in the development of ALL.
- Open Access
- 11 October 2023
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in Experimental Oncology
- Vol. 45 (2) , 203-210
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) POLYMORPHIC VARIATIONS (-216G/T & −191 C/A) POSE A HIGH RISK TO PATIENTS WITH MALIGNANT GLIOMA
Background. Malignant gliomas are the most frequent and lethal brain tumors. Their molecular aspects remain intangible but current studies have pointed to certain genetic polymorphic loci that pose the risk. The polymorphic sequence variations of the epidermal growth factor receptor gene (EGFR) pathway play a vital role in the glioma risk, and the EGFR variants (216G>T and 191C>A) are identified to affect the risk for the development of different tumors including glioma. Aim. To examine genetic variations of EGFR T rs712829 (216G/T) and rs712830 (191C>A) with respect to glioma risk. Materials and Methods. 129 confirmed glioma cases were genotyped against 180 malignancy-free healthy controls by polymerase chain reaction-restriction fragment length polymorphism technique (RFLP). Results. The frequency of the TT homozygous variant of the EGFR -216 G/T genotype differed significantly between cases and controls (49.6% vs. 23.0%) (p < 0.0001). The EGFR -216 G>T allele ‘T’ was found significantly more frequently in cases (0.56 vs. 0.33 in controls; p < 0.0001). The EGFR -191C>A homozygous ‘AA’ genotype was implicated significantly more frequently in cases than in controls (p < 0.0001). The distribution of the ‘A’ variant allele was also more frequent in cases (41.9%) than in controls (14.0%) (0.55 vs. 0.30; p < 0.0001). TC and TA haplotypes showed varied frequency in cases and controls. Conclusion. EGFR -216 G>T and -191 C>A variants and haplotypes (TA and TC) of the EGFR gene are very strong risk factors in the development of glioma in the Kashmiri population.
- 11 October 2023
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in Experimental Oncology
- Vol. 45 (2) , 203-210
Open AccessEPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) POLYMORPHIC VARIATIONS (-216G/T & −191 C/A) POSE A HIGH RISK TO PATIENTS WITH MALIGNANT GLIOMA
Background. Malignant gliomas are the most frequent and lethal brain tumors. Their molecular aspects remain intangible but current studies have pointed to certain genetic polymorphic loci that pose the risk. The polymorphic sequence variations of the epidermal growth factor receptor gene (EGFR) pathway play a vital role in the glioma risk, and the EGFR variants (216G>T and 191C>A) are identified to affect the risk for the development of different tumors including glioma. Aim. To examine genetic variations of EGFR T rs712829 (216G/T) and rs712830 (191C>A) with respect to glioma risk. Materials and Methods. 129 confirmed glioma cases were genotyped against 180 malignancy-free healthy controls by polymerase chain reaction-restriction fragment length polymorphism technique (RFLP). Results. The frequency of the TT homozygous variant of the EGFR -216 G/T genotype differed significantly between cases and controls (49.6% vs. 23.0%) (p < 0.0001). The EGFR -216 G>T allele ‘T’ was found significantly more frequently in cases (0.56 vs. 0.33 in controls; p < 0.0001). The EGFR -191C>A homozygous ‘AA’ genotype was implicated significantly more frequently in cases than in controls (p < 0.0001). The distribution of the ‘A’ variant allele was also more frequent in cases (41.9%) than in controls (14.0%) (0.55 vs. 0.30; p < 0.0001). TC and TA haplotypes showed varied frequency in cases and controls. Conclusion. EGFR -216 G>T and -191 C>A variants and haplotypes (TA and TC) of the EGFR gene are very strong risk factors in the development of glioma in the Kashmiri population.
- Open Access
- 2 March 2023
- Published by Springer Nature in Research Square
Androgen receptor signalling transactivator lncRNAs PRNCR1 and PCGEM contribute to PCOS pathogenesis
Polycystic ovary syndrome is the most common endocrine, reproductive disorder of women in their reproductive years. It is commonly considered as an androgenic disorder. Apart from high circulating testosterone levels, hyperandrogenism can also be attributed to the hyperactive androgen receptor (AR). Androgen receptor mediated signalling involves the association of multiple coactivators and corepressors and any aberrant activity of these factors may disrupt the normal transcriptional activity of AR and hence may act as contributing factors in the pathophysiology of various diseases. LncRNAs prostate cancer associated non-coding RNA 1 (PRNCR1) and prostate cancer gene expression marker 1 (PCGEM1) act as androgen receptor coactivator lncRNAs. The study was aimed at determining the association of lncRNAs PRNCR1 and PCGEM1 with PCOS. In this case-control study, a total of 178 participants were recruited these included 105 PCOS cases and 73 age-matched healthy controls. The Anthropometric, Metabolic and hormonal characteristics of the participants were determined. Total RNA was isolated from peripheral mononuclear blood cells and reverse transcribed into cDNA. Quantitative real-time PCR (qPCR) was done to study the expression pattern on lncRNAs. The association between different hormonal and metabolic parameters with the expression of PRNCR1 and PCGEM1 was determined by correlation analysis. Our study for the first time demonstrated that lncRNA PRNCR1 and PCGEM1 are overexpressed in Kashmiri women with PCOS. The expression levels of PRNCR1 (PRNCR1, 5.26 ± 1.77 versus 1.22 ± 0.73; P < 0.001) and PCGEM1 (PCGEM1, 3.39 ± 1.88 versus 1.23 ± 0.74; P < 0.001) were significantly higher in PCOS women compared to controls. Furthermore, lncRNA PRNCR1 showed a positive correlation with testosterone (P < 0.001).
- 2 March 2023
- Published by Springer Nature in Research Square
Open AccessAndrogen receptor signalling transactivator lncRNAs PRNCR1 and PCGEM contribute to PCOS pathogenesis
Polycystic ovary syndrome is the most common endocrine, reproductive disorder of women in their reproductive years. It is commonly considered as an androgenic disorder. Apart from high circulating testosterone levels, hyperandrogenism can also be attributed to the hyperactive androgen receptor (AR). Androgen receptor mediated signalling involves the association of multiple coactivators and corepressors and any aberrant activity of these factors may disrupt the normal transcriptional activity of AR and hence may act as contributing factors in the pathophysiology of various diseases. LncRNAs prostate cancer associated non-coding RNA 1 (PRNCR1) and prostate cancer gene expression marker 1 (PCGEM1) act as androgen receptor coactivator lncRNAs. The study was aimed at determining the association of lncRNAs PRNCR1 and PCGEM1 with PCOS. In this case-control study, a total of 178 participants were recruited these included 105 PCOS cases and 73 age-matched healthy controls. The Anthropometric, Metabolic and hormonal characteristics of the participants were determined. Total RNA was isolated from peripheral mononuclear blood cells and reverse transcribed into cDNA. Quantitative real-time PCR (qPCR) was done to study the expression pattern on lncRNAs. The association between different hormonal and metabolic parameters with the expression of PRNCR1 and PCGEM1 was determined by correlation analysis. Our study for the first time demonstrated that lncRNA PRNCR1 and PCGEM1 are overexpressed in Kashmiri women with PCOS. The expression levels of PRNCR1 (PRNCR1, 5.26 ± 1.77 versus 1.22 ± 0.73; P < 0.001) and PCGEM1 (PCGEM1, 3.39 ± 1.88 versus 1.23 ± 0.74; P < 0.001) were significantly higher in PCOS women compared to controls. Furthermore, lncRNA PRNCR1 showed a positive correlation with testosterone (P < 0.001).
- Open Access
Insulin Receptor Substrate 1 Gly972Arg (rs1801278) Polymorphism Is Associated with Obesity and Insulin Resistance in Kashmiri Women with Polycystic Ovary Syndrome
Background: Polycystic ovary syndrome (PCOS) is commonly associated with metabolic abnormalities such as hyperinsulinemia, insulin resistance and obesity. The genetic variants of genes regulating insulin action, expression and regulation are suggested as possible factors involved in development and severity of clinical manifestations in PCOS. Aim: We investigated whether IRS-1Gly972Arg (rs1801278) polymorphism is associated with increased risk of PCOS in Kashmiri women. The correlation of various clinical, metabolic and hormonal markers with rs1801278 single nucleotide polymorphism was analyzed. The genotypic–phenotypic association of clinical manifestations of PCOS with the tested genetic variant was also assessed. Results: There were no significant differences in allele frequency (OR = 0.87, CI = 0.59–1.29, χ2 = 0.456, p = 0.499) or genotypic distribution (χ2 = 3.73, p = 0.15) between PCOS women and controls. No significant association was also found in the dominant (OR = 1.63, χ2 = 0.377, p = 0.53), recessive (OR = 0.79, χ2 = 1.01, p = 0.31) or heterozygote vs. homozygote (OR = 1.34, χ2 = 1.53, p = 0.22) genotype model analysis. The genotype–phenotype correlation analysis showed that the Arg allele was significantly associated with increased central adiposity markers hip circumference (p = 0.012), and body adiposity index BAI (p = 0.002) in the recessive model in PCOS women. The two-hour glucose (p = 0.04) and insulin resistance marker HOMA (p = 0.44) were significantly higher in Arg allele carriers. The androgen excess markers dehydroepiandrosterone sulfate DHEAS (p = 0.02), Ferriman–Gallwey score (p = 0.012), prevalence of acne, alopecia and hirsutism (all p < 0.01) were significantly elevated in the wild-type GG genotype. Conclusions:IRS-1Gly972Arg genetic variant does not increase the risk of PCOS in Kashmiri women. However, this polymorphism is associated with clinical manifestations of insulin resistance, obesity and hyperandrogenism, suggesting its possible role in variable phenotypic manifestations of PCOS.
Open AccessInsulin Receptor Substrate 1 Gly972Arg (rs1801278) Polymorphism Is Associated with Obesity and Insulin Resistance in Kashmiri Women with Polycystic Ovary Syndrome
Background: Polycystic ovary syndrome (PCOS) is commonly associated with metabolic abnormalities such as hyperinsulinemia, insulin resistance and obesity. The genetic variants of genes regulating insulin action, expression and regulation are suggested as possible factors involved in development and severity of clinical manifestations in PCOS. Aim: We investigated whether IRS-1Gly972Arg (rs1801278) polymorphism is associated with increased risk of PCOS in Kashmiri women. The correlation of various clinical, metabolic and hormonal markers with rs1801278 single nucleotide polymorphism was analyzed. The genotypic–phenotypic association of clinical manifestations of PCOS with the tested genetic variant was also assessed. Results: There were no significant differences in allele frequency (OR = 0.87, CI = 0.59–1.29, χ2 = 0.456, p = 0.499) or genotypic distribution (χ2 = 3.73, p = 0.15) between PCOS women and controls. No significant association was also found in the dominant (OR = 1.63, χ2 = 0.377, p = 0.53), recessive (OR = 0.79, χ2 = 1.01, p = 0.31) or heterozygote vs. homozygote (OR = 1.34, χ2 = 1.53, p = 0.22) genotype model analysis. The genotype–phenotype correlation analysis showed that the Arg allele was significantly associated with increased central adiposity markers hip circumference (p = 0.012), and body adiposity index BAI (p = 0.002) in the recessive model in PCOS women. The two-hour glucose (p = 0.04) and insulin resistance marker HOMA (p = 0.44) were significantly higher in Arg allele carriers. The androgen excess markers dehydroepiandrosterone sulfate DHEAS (p = 0.02), Ferriman–Gallwey score (p = 0.012), prevalence of acne, alopecia and hirsutism (all p < 0.01) were significantly elevated in the wild-type GG genotype. Conclusions:IRS-1Gly972Arg genetic variant does not increase the risk of PCOS in Kashmiri women. However, this polymorphism is associated with clinical manifestations of insulin resistance, obesity and hyperandrogenism, suggesting its possible role in variable phenotypic manifestations of PCOS.